Related Experiment Video

Updated: Jun 1, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Transforming growth factor beta in pancreatic cancer

Andreas Hilbig1, Helmut Oettle

  • 1Universitätsklinikum Münster, Hämotology & Onkologie, Münster, Albert-Schweitzer-Str. 33, Germany. andreas.hilbig@ukmuenster.de

Current Pharmaceutical Biotechnology
|May 31, 2011
PubMed

Insights

Pancreatic cancer treatment is challenging. Inhibiting transforming growth factor beta 2 (TGF-β2) with trabedersen shows promise for improving patient prognosis by targeting its synthesis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Pancreatic cancer presents significant clinical challenges due to high incidence and mortality rates.
  • The transforming growth factor beta (TGF-β) pathway is implicated in pancreatic carcinoma progression.
  • Current therapeutic strategies targeting the TGF-β pathway include small molecule inhibitors, neutralizing antibodies, and antisense compounds.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting transforming growth factor beta 2 (TGF-β2) synthesis in pancreatic cancer.
  • To evaluate trabedersen (AP 12009), an antisense oligonucleotide, as a strategy to reduce TGF-β2 levels.

Main Methods:

  • The study focuses on the inhibition of TGF-β2 synthesis.
  • Trabedersen (AP 12009), an antisense oligonucleotide, is utilized as the primary therapeutic agent.

Main Results:

  • Elevated TGF-β2 levels in serum or tumor tissue correlate with a poor prognosis in pancreatic cancer patients.
  • Inhibition of TGF-β2 synthesis represents a promising therapeutic avenue.

Conclusions:

  • Targeting TGF-β2 synthesis with trabedersen (AP 12009) offers a promising approach for pancreatic cancer treatment.
  • Reducing TGF-β2 levels may improve outcomes for patients with pancreatic cancer.

More Related Videos

Growing Desmoplastic Three-Dimensional Pancreatic Cancer Spheroids from Co-Culture03:42

Growing Desmoplastic Three-Dimensional Pancreatic Cancer Spheroids from Co-Culture

Published on: September 27, 2024

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...